DAVAO DOCTORS COLLEGE

Gen. Malvar St., Davao City

Nursing Program

DRUG STUDY

Name of Patient: Patient P.S Date of Admission: 03/01/2023 Room: 210 Age: 27 years old
Sex: Female Civil Status: Single Chief Complaint: feeling of fatiguability, palpitations, severe headache, nausea and vomiting, tremors and moist hands.
Religion: Roman Catholic Attending Physician: Dr. Ngo
DATE MODE OF SIDE ADVERSE NURSING
MEDICATION DOSAGE INDICATIONS CONTRAINDICATIONS
ORDERED ACTION EFFECTS EFFECTS RESPONSIBILITY

GENERIC NAME: Lithium inhibits 600 mg−1000 Bipolar disorders, Hypersensitivity to Occasional: Vomiting, • Clinical
Lithium thyroid hormone mg daily (300 severe lithium. Severely Fine hand Diarrhea, assessment
release from the mg every 8 hyperthyroidism debilitated pts, severe tremor, Drowsiness, of
thyroid gland it hours) cardiovascular disease, polydipsia, Confusion, therapeutic
can be used as concurrent use with polyuria, mild Incoordination, effect,
BRAND NAME: an adjunct diuretics, severe nausea. Course hand tolerance to
Lithobid therapy in the dehydration, severe Rare: Weight tremor, Muscle drug effect is
management of renal disease, severe gain, twitching, T- necessary
severe sodium depletion or bradycardia, wave for correct
hyperthyroidism. dehydration. tachycardia, depression on dosing-level
CLASSIFICATION: acne, rash, EKG managemen
Pharma: Mood- muscle t.
stabilizing agent twitching, • Assess
Clinical: Antimanic peripheral behavior,
cyanosis, appearance,
ROUTE: pseudotumor emotional
OD 300 mg cerebri (eye status,
pain, response to
headache, environment
tinnitus, vision , speech
disturbances). pattern,
thought
content.
• Monitor
 serum
lithium
concentratio
ns, CBC
with
differential,
urinalysis,
creatinine
clearance.
• Monitor
renal,
hepatic,
thyroid,
cardiovascul
ar function;
serum
electrolytes.
• Assess for
increased
urinary
output,
persistent
thirst.
Report
polyuria,
prolonged
vomiting,
diarrhea,
fever to
physician
(may need
to
temporarily
reduce or
discontinue
dosage).
• Monitor for
 signs of
lithium
toxicity.
• Assess for
therapeutic
response
(interest in
surrounding
s,
improvemen
t in self-care,
increased
ability to
concentrate,
relaxed
facial
expression
• Monitor
lithium
levels q3–
4days at
initiation of
therapy
(then q1–
2mos).
• Obtain
lithium
levels 8–12
hrs
postdose.